Tag Archives: PAD

Patients presenting with symptomatic PAD are at high risk of ischaemic stroke, myocardial infarction and progression of the PAD.2 Recent data suggest that half of chronic total occlusions occurring below the knee are thomboembolic in origin, and not due to in situ atherosclerosis as believed previously.3 Accordingly, treating PAD patients with antithrombotic agents may have benefits in reducing major adverse cardiovascular events (MACE).8 The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial demonstrated that adding rivaroxaban 2.5 mg twice daily to aspirin 100 mg once daily in patients with PAD reduced MACE

Mike is a Professor of Medicine at Harvard Medical School, and an interventional cardiologist at the Beth Israel Deaconess in Boston, USA. He is the founder and director of the academic research organization PERFUSE and has been principal investigator or has led core services for over 120 clinical trials, the results of which have been published in leading journals. Mike is also an active user of Twitter (@CMichaelGibson). Amar is a Consultant in Diabetes and Endocrinology at the Good Hope Hospital, Sutton Coldfield, West Midlands. A regular contributor to the journal, Amar has previously been very active in the Young Diabetologists and Endoc

Self-monitoring of type 2 diabetes cuts costs Self-monitoring of type 2 diabetes used in combination with an electronic feedback system results in considerable savings on health care costs and also travel costs for patients, especially in sparsely populated areas, a new study shows. The study, carried out in Northern Karelia by the University of Eastern Finland, found that by replacing half of the required follow-up visits for type 2 diabetes with self-measurements and electronic feedback, total costs of glycated haemoglobin monitoring were reduced by nearly 60%. The annual per-patient cost was down from 280 euros to 120 euros. Fewer follow-u